Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights.
Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights.
复制标题
安非他酮抗吸烟作用的行为和药理学机制：最近的临床前和临床见解。
DOI：
10.1016/j.ejphar.2008.12.009
复制
发表时间：
2009
影响因子：
5
通讯作者：
N. Paterson
中科院分区：
文献类型：
--
作者：
N. Paterson
Ongoing studies continue to explore the behavioural and pharmacological effects of bupropion in smoking cessation studies and animal models of nicotine dependence. In the present review, the components of nicotine dependence that form the most likely targets of bupropion are identified within the context of an expanding preclinical and clinical literature regarding the anti-addictive properties of bupropion. Second, preclinical and clinical data that implicate specific pharmacological modes of action of bupropion in mediating the anti-smoking effects of the compound are discussed. Third, it is suggested that the unique mixed pharmacological profile of bupropion provides (1) attenuation of the multiple negative consequences of withdrawal via blockade of dopamine and noradrenaline reuptake; (2) replacement of the reward-facilitating and subjective effects of nicotine via blockade of dopaminergic reuptake; (3) attenuation of the rewarding effects of acute nicotine by nicotinic acetylcholine receptor blockade. The importance of species differences in bupropion metabolism in the interpretation of preclinical studies is highlighted. Finally, future studies are suggested to address identified gaps in the knowledge: most importantly, to provide stronger evidence for the role of noradrenaline reuptake inhibition in bupropion-induced attenuation of nicotine withdrawal. Future studies aimed at providing more evidence for the three-fold nature of the anti-smoking effects of bupropion are also suggested, along with the possibility of utilizing adjunct therapies to improve smoking cessation rates.
登录
查看更多内容
DOI：
--
发表时间：
1989-10
期刊：
The Journal of pharmacology and experimental therapeutics
影响因子：
--
作者：
J. Bergman;B. Madras;S. E. Johnson;R. Spealman
通讯作者：
J. Bergman;B. Madras;S. E. Johnson;R. Spealman
长期自我施用安非他酮和诺米芬辛后多巴胺转运蛋白的差异调节。
DOI：
--
发表时间：
1997
期刊：
The Journal of pharmacology and experimental therapeutics.
影响因子：
--
作者：
Tella,SR;Ladenheim,B;Cadet,JL
通讯作者：
Cadet,JL
哌醋甲酯、安非他酮和三唑仑对接受过 d-苯丙胺训练的人的辨别刺激和参与者评价效果。
DOI：
10.1037//1064-1297.6.1.32
发表时间：
1998
期刊：
Experimental and clinical psychopharmacology.
影响因子：
--
作者：
Rush,CR;Kollins,SH;Pazzaglia,PJ
通讯作者：
Pazzaglia,PJ
DOI：
10.1073/pnas.0401080101
发表时间：
2004-05-25
影响因子：
11.1
作者：
Cryan, JF;O'Leary, OF;Lucki, I
通讯作者：
Lucki, I
安非他酮 SR 和实际戒烟咨询：结果的预测因素。
DOI：
10.1080/14622200310001646903
发表时间：
2003
期刊：
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
影响因子：
--
作者：
Swan,GaryE;Jack,LisaM;Curry,Sue;Chorost,Michael;Javitz,Harold;McAfee,Tim;Dacey,Sara
通讯作者：
Dacey,Sara